COVID-19 Vaccine Useful: Moderna Claims Success in Testing Skin Cancer Vaccine

Spread the love

Share

  • COVID-19 vaccine came in handy: Moderna claims success in vaccine testing skin cancer

    send to Telegram

  • COVID-19 vaccine came in handy: Moderna claims success in skin cancer vaccine testing

    share on Facebook

  • COVID-19 vaccine came in handy: Moderna claims success in skin cancer vaccine testing

    tweet

  • COVID-19 vaccine came in handy: Moderna claims success in skin cancer vaccine testing

    send to Whatsapp

  • COVID-19 vaccine came in handy: Moderna claims success in skin cancer vaccine testing

    send to Messenger

COVID-19 vaccine came in handy: Moderna claims success in skin cancer vaccine testing

Moderna and Merck pioneered messenger RNA technology to create personalized vaccines.

Related video

mRNA technology has shown its effectiveness in developing vaccines against COVID-19. After such success, scientists have suggested that this technology could be just as effective in fighting other viruses, as well as diseases such as cancer, writes GMA News Online.

Pharmacological companies Moderna and Merck used this technology to create personalized vaccines for skin cancer patients. And it seems to be showing positive results.

Focus. Technology has its own Telegram channel. Subscribe to keep up to date with the latest and exciting news from the world of science!

150 people took part in the preliminary study. All of them underwent surgery to remove melanoma surgically, and then received up to 9 doses of an experimental vaccine in combination with a drug to treat skin cancer. The results of the study show that the risk of death or relapse was reduced by 44% compared with patients who received only the immunotherapy drug.

According to Moderna CEO Stephane Bansel, today's results are very encouraging and hold out hope for a breakthrough in skin cancer treatment. The study shows that the mRNA that changed the course of the coronavirus pandemic is also effective for the treatment of melanoma.

Note that the results of the study have not yet been licensed, and therefore Moderna and Merck (MSD), will publish a fuller report only after some time. It is planned that as early as 2023, companies will launch a phase III trial, in which more recipients will take part.

Scientists note that the new melanoma vaccine is aimed at using the immune system – that is, the patient will be able to generate an individual antitumor response specific to its tumor mutation.

Today, melanoma is the worst form of skin cancer. In 2020 alone, this type of skin cancer was diagnosed in 325,000 people. Preliminary estimates show that about 8,000 people will die from melanoma this year.